Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 536

1.

Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.

El-Sherif O, Khoo S, Solas C.

Curr Opin HIV AIDS. 2015 Sep;10(5):348-54. doi: 10.1097/COH.0000000000000185.

PMID:
26248122
2.

Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients.

Del Bello D, Nagy FI, Hand J, Khedemi R, Lécluse-Barth J, Dieterich D, Piroth L.

Curr Opin HIV AIDS. 2015 Sep;10(5):337-47. doi: 10.1097/COH.0000000000000182.

PMID:
26248121
3.

Significant Decreases in both Total and Unbound Lopinavir and Amprenavir Exposures during Co-administration: ACTG Protocol A5143/A5147s Results.

Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC.

J Acquir Immune Defic Syndr. 2015 Jul 30. [Epub ahead of print]

PMID:
26230332
4.

Treatment of Chronic HCV Genotype 1 Coinfection.

Boesecke C, Rockstroh JK.

Curr HIV/AIDS Rep. 2015 Sep;12(3):326-35. doi: 10.1007/s11904-015-0278-4.

PMID:
26228050
5.

Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.

Esposito I, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Benítez-Gutiérrez L, Peña JM, Soriano V.

Expert Opin Drug Saf. 2015 Sep;14(9):1421-34. doi: 10.1517/14740338.2015.1073258. Epub 2015 Jul 28.

PMID:
26212044
6.

Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?

Arends JE, Lieveld FI, Boeijen LL, de Kanter CT, van Erpecum KJ, Salmon D, Hoepelman AI, Asselah T, Ustianowski A.

J Hepatol. 2015 Jul 14. pii: S0168-8278(15)00462-6. doi: 10.1016/j.jhep.2015.06.034. [Epub ahead of print] Review.

PMID:
26186987
7.

Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents.

Audrey C, Raffaele B.

Curr Opin HIV AIDS. 2015 Sep;10(5):361-8. doi: 10.1097/COH.0000000000000186.

PMID:
26185921
8.

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.

Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J; Swiss HIV Cohort Study.

PLoS One. 2015 Jul 15;10(7):e0133028. doi: 10.1371/journal.pone.0133028. eCollection 2015.

9.

Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.

Osinusi A, Townsend K, Kottilil S.

JAMA. 2015 Jul 14;314(2):186-7. doi: 10.1001/jama.2015.6621. No abstract available.

PMID:
26172900
10.

Drug-Drug Interactions in Patients Co-infected With HCV and HIV.

Nozaki Y, Yanase M, Masaki N.

JAMA. 2015 Jul 14;314(2):186. doi: 10.1001/jama.2015.6618. No abstract available.

PMID:
26172899
11.

Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person.

El-Sherif O, Back D.

Curr HIV/AIDS Rep. 2015 Sep;12(3):336-43. doi: 10.1007/s11904-015-0277-5.

PMID:
26159742
12.

Emerging Challenges in Managing Hepatitis B in HIV Patients.

Soriano V, Labarga P, de Mendoza C, Peña JM, Fernández-Montero JV, Benítez L, Esposito I, Barreiro P.

Curr HIV/AIDS Rep. 2015 Sep;12(3):344-52. doi: 10.1007/s11904-015-0275-7.

PMID:
26156570
13.

Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.

Toussaint-Miller KA, Andres J.

Ann Pharmacother. 2015 Sep;49(9):1015-30. doi: 10.1177/1060028015592015. Epub 2015 Jul 2. Review.

PMID:
26139639
14.

Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.

Bollen P, Reiss P, Schapiro J, Burger D.

Expert Opin Drug Saf. 2015 Sep;14(9):1457-72. doi: 10.1517/14740338.2015.1059818. Epub 2015 Jul 3.

PMID:
26134478
15.

Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.

Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, Londeix P, Forette C, Momenghalibaf A, Verster A, Swan T.

Int J Drug Policy. 2015 May 18. pii: S0955-3959(15)00137-1. doi: 10.1016/j.drugpo.2015.05.004. [Epub ahead of print]

PMID:
26074094
16.

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

Fazel Y, Lam B, Golabi P, Younossi Z.

Expert Opin Drug Saf. 2015 Aug;14(8):1317-26. doi: 10.1517/14740338.2015.1053868. Epub 2015 Jun 4.

PMID:
26043900
17.

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.

Chen TY, Jain MK.

AIDS Patient Care STDS. 2015 Jun;29(6):329-37. doi: 10.1089/apc.2014.0247.

PMID:
26020726
18.

Hepatitis C virus-HIV-coinfected patients and liver transplantation.

Kardashian AA, Price JC.

Curr Opin Organ Transplant. 2015 Jun;20(3):276-85. doi: 10.1097/MOT.0000000000000199. Review.

PMID:
25944240
19.

Synthesis, crystal structures and docking studies of 2,7-diphenyl-1,4-diazepan-5-one derivatives.

Velusamy M, Sreenivasan S, Kandasamy R, Subbu P, Paramasivam S, Mondikalipudur Nanjappagounder P.

Chem Cent J. 2015 Apr 8;9:17. doi: 10.1186/s13065-015-0094-3. eCollection 2015.

20.

Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.

Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A.

Ann Pharmacother. 2015 Jul;49(7):796-807. doi: 10.1177/1060028015581848. Epub 2015 Apr 22. Review.

PMID:
25902733
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk